
Release date: 2026-04-21 15:13:23 Article From: Lucius Laos Recommended: 8
Before starting Adagrasib, be sure to tell your healthcare team about all of your medical history, especially the following conditions:
Heart problems: including heart failure, congenital long QT syndrome, or any history of arrhythmias. If you have congenital long QT syndrome or your current ECG shows a prolonged QTc interval, you should not use Adagrasib.
Liver disease: history of hepatitis, cirrhosis, or abnormal liver function.
Electrolyte imbalances: especially abnormal blood potassium or blood magnesium levels.
Other medications: including all prescription drugs, over-the-counter drugs, vitamins, and herbal supplements. Taking Adagrasib with certain medications (such as some antiarrhythmics, antifungals, antibiotics) may affect each other's effectiveness or increase the risk of side effects. Keep a complete list of your medications and show it to your doctor and pharmacist at each visit.
During pregnancy: There are currently no adequate data to indicate whether Adagrasib may cause harm to a fetus. Tell your doctor if you are pregnant or plan to become pregnant before taking this medication. Effective contraception is recommended during treatment.
During breastfeeding: It is unknown whether Adagrasib passes into breast milk. To avoid potential risk to an infant, stop breastfeeding during treatment and for at least 1 week after the last dose.
Fertility: Adagrasib may cause fertility problems in patients of all sexes, affecting your ability to have a child in the future. If you have plans to have a child or have concerns about fertility, talk to your doctor in advance.
Store Adagrasib tablets in the original container, which has a child-resistant design and contains a desiccant packet to keep the tablets dry. Do not remove the desiccant packet, and do not eat or swallow the desiccant.
Store at room temperature (20°C to 25°C, i.e., 68°F to 77°F), away from high heat and humidity.
Keep all medications, including Adagrasib, out of the reach of children and pets.
Do not use Adagrasib for any condition other than the one for which it was prescribed, and do not share the medication with others, even if they have similar symptoms, as it may harm them.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2572025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4772024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2622025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2722025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2492025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2952025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2532025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2382025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: